TRVI
NASDAQTrevi Therapeutics Inc.
Price$13.41-0.45 (-3.25%)
01:45 PM07:45 PM
News · 26 weeks50-40%
2025-12-142026-06-07
Mix2790d
- SEC Filings11(41%)
- Other5(19%)
- Insider5(19%)
- Offering4(15%)
- Earnings2(7%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Mathers Edward T4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- SECTrevi Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
- INSIDERSEC Form 4 filed by Director Colangelo Dominick4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- INSIDERSEC Form 4 filed by Director Vanlent Anne4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- INSIDERSEC Form 4 filed by Director Heffernan Michael Thomas4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- INSIDERSEC Form 4 filed by Director Meeker David P4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Trevi Therapeutics Inc.SCHEDULE 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
- SECSEC Form 10-Q filed by Trevi Therapeutics Inc.10-Q - Trevi Therapeutics, Inc. (0001563880) (Filer)
- SECTrevi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
- PRTrevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesCompleted follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and continued pipeline advancement Clinical development plans remain on track across all chronic cough indications Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung
- PRTrevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International ConferencePrimary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyses by baseline cough count and background anti-fibrotic use An exploratory post-hoc analysis of the effects of nalbuphine ER and placebo on cough bouts from the Phase 2b CORAL trial in patients with IPF-related chronic cough and the Phase 2a RIVER trial in patients with refractory chronic cough Drug–drug interaction data from a Phase 1 study evaluating pharmacokinetics and safety following co-administration of nalbuphine ER with pirfenidone or nintedanib NEW HAVEN, Conn., April 30, 2026 (GLO
- PRTrevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 5, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2026. Conference Call and WebcastTo register for the live conference call and we
- PRTrevi Therapeutics to Participate in Upcoming May EventsNEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in several upcoming events in May. Trevi Therapeutics Investor and Analyst DayMay 7, 2026, Midtown New York, New York10:00 a.m. to 12:00 p.m. ET, followed by lunch and open discussionsRepresentatives: Trevi senior management will be joined by key opinion leaders
- SECSEC Form DEF 14A filed by Trevi Therapeutics Inc.DEF 14A - Trevi Therapeutics, Inc. (0001563880) (Filer)
- SECSEC Form DEFA14A filed by Trevi Therapeutics Inc.DEFA14A - Trevi Therapeutics, Inc. (0001563880) (Filer)
- PRTrevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesNEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the closing of its previously announced underwritten public offering of 13,340,000 shares of its common stock at a public offering price of $13.00 per share, which includes 1,740,000 additional shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of
- SECSEC Form 424B5 filed by Trevi Therapeutics Inc.424B5 - Trevi Therapeutics, Inc. (0001563880) (Filer)
- SECTrevi Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
- PRTrevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common StockNEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 11,600,000 shares of its common stock at a public offering price of $13.00 per share, for total proceeds of approximately $150 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of t
- SECSEC Form 424B5 filed by Trevi Therapeutics Inc.424B5 - Trevi Therapeutics, Inc. (0001563880) (Filer)
- PRTrevi Therapeutics Announces Proposed Public Offering of Common StockNEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. All of the shares in the offering are being offered by Trevi. In addition, Trevi expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of the shares of its common
- SECSEC Form PRE 14A filed by Trevi Therapeutics Inc.PRE 14A - Trevi Therapeutics, Inc. (0001563880) (Filer)
- PRTrevi Therapeutics to Participate in Upcoming EventsNEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following events. 25th Annual Needham Virtual Healthcare ConferenceApril 13 – 16, 2026, Virtual Fireside Chat: April 13, 12:45 p.m. ET Trevi Representatives: Jennifer Good, President and CEO, and David Hastings, CFORaymond James 2026 Biotech Innovatio
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Trevi Therapeutics Inc.SCHEDULE 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
- SECSEC Form 10-K filed by Trevi Therapeutics Inc.10-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
TRVI FAQ
7 questionsWhat does Trevi Therapeutics Inc. do?
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with...Where does TRVI stock trade?
Trevi Therapeutics Inc. (TRVI) is listed on NASDAQ.What sector and industry is TRVI in?
Trevi Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Trevi Therapeutics Inc. go public?
Trevi Therapeutics Inc. (TRVI) completed its IPO in 2019.What are analysts saying about TRVI?
Trevi Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $1300.00 price target on 2025-11-13. Recent price targets range from $700.00 to $2900.00.What companies are similar to TRVI?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TRVI side-by-side with any of them on Quantisnow.How can I track TRVI on Quantisnow?
Quantisnow aggregates Trevi Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TRVI to receive live email and push alerts on every new disclosure.